• Florence Tubach, Philippe Ravaud, Dorcas Beaton, Maarten Boers, Claire Bombardier, David T Felson, Desireé van der Heijde, George Wells, and Maxime Dougados.
• Département d'Epidémiologie, Biostatistique et Recherche Clinique, Hôpital Bichat, Paris, France. florence.tubach@bch.aphp.fr
• J Rheumatol. 2007 May 1;34(5):1188-93.

AbstractThe concepts of minimal clinically important improvement (MCII) and patient acceptable symptomatic state (PASS) could help in interpreting results of trials involving patient-reported outcomes by translating the response at the group level (change in mean scores) into more clinically meaningful information by addressing the patient level as "therapeutic success (yes/no)." The aims of the special interest group (SIG) at OMERACT 8 were to discuss specific issues concerning the MCII and PASS concepts, especially the wording of the external anchor questions used to determine the MCII and PASS estimates, and to move toward a consensus for the cutoff values to use as the MCII and PASS in the different outcome criteria. The purpose of this SIG at OMERACT 8 was to inform participants of the MCII and PASS concepts and to agree on MCII and PASS values for pain, patient global assessment, and functional impairment.

11 keywords...

hide…